Medical/Pharmaceuticals
ASCO 2022 | Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL
SUZHOU, China and ROCKVILLE, Md., June 7, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released the updated results from a Pha...
2022-06-08 08:00
2343
First Patient Enrolled in SELUTION SLR IDE BTK Study
LEIPZIG, Germany, June 8, 2022 /PRNewswire/ -- The first patient has been
enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK clinical trial
involving SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, just
one week after receiving IDE approval.
2022-06-08 08:00
3668
Innovent Announces Phase 2 study of Mazdutide（IBI362） in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints
SAN FRANCISCO and SUZHOU, China, June 8, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and ot...
2022-06-08 08:00
4220
Frost & Sullivan Awards EBSCO Information Services for Delivering Innovative Solutions to Access Medical Research Information for Healthcare Providers
Clinical Decisions product suite from EBSCO earns recognition for modern evidence-based resources that support clinical decision-making, enhance patient satisfaction, and improve outcomes SAN ANTONIO, June 7, 2022 /PRNewswire/ -- Based on its recent analysis of the clinical decision support syst...
2022-06-07 21:00
3172
Nature Scientific Reports to publish novel decentralized federated AI learning algorithm that connects globally distributed data silos containing private and poor-quality data
SAN FRANCISCO, June 7, 2022 /PRNewswire/ -- Nature Scientific Reports journal has published results of a new decentralized federated AI learning algorithm from Presagen that can train AI on data that is distributed globally, without having to move private data to a central location. The breakthro...
2022-06-07 20:38
2532
The 3rd BIO International Convention 2022 is Approaching
SAN DIEGO, June 7, 2022 /PRNewswire/ -- With the 3rd BIO International Convention 2022 soon approaching, Neurophth Therapeutics is looking forward to discussing collaboration opportunities in gene therapy for both rare and common ocular diseases. Neurophth Therapeutics is a leading clinical-stag...
2022-06-07 19:23
2536
PHASE II STUDY OF PAXALISIB IN BRAIN METASTASES ADVANCES TO EXPANSION STAGE IN BREAST CANCER BRAIN METASTASES COHORT
SYDNEY, June 7, 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II, genomically-guided study of multiple therapies in patients with brain metastases, led by the Alliance for Clinical Trials in Oncology (NC...
2022-06-07 19:00
3127
Molecular Stethoscope, Inc. announces new investment from the Alzheimer's Drug Discovery Foundation
Investment by the ADDF will accelerate the translation of Molecular Stethoscope's cf-mRNA liquid biopsy technology platform into products and services for the diagnosis and management of Alzheimer's disease SOUTH SAN FRANCISCO, Calif., June 7, 2022 /PRNewswire/ -- Molecular Stethoscope, a leadin...
2022-06-07 18:00
2163
Chordia Therapeutics Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting
KANAGAWA, Japan, June 7, 2022 /PRNewswire/ -- Chordia Therapeutics Inc. ("Chordia"), a biotech company engaged in the research and development of novel therapies for cancers, today announced that it has presented the interim results from the Phase 1 clinical trial of CTX-712, a selective pan-CDC-...
2022-06-07 14:00
2870
Chordia Therapeutics Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting
KANAGAWA, Japan, June 7, 2022 /PRNewswire/ -- Chordia Therapeutics Inc. ("Chordia"), a biotech company engaged in the research and development of novel therapies for cancers, today announced that it has presented the interim results from the Phase 1 clinical trial of CTX-712, a selective pan-CDC-...
2022-06-07 14:00
2127
SCG Cell Therapy And A*STAR's IMCB Collaborate To Accelerate Clinical Translation of Immune Cell-based Therapy
* The collaboration agreement works toward accelerating the study of SCG's immunotherapy pipeline and candidates such as CAR-T, TCR-T therapies, antibodies, and vaccines. * SCG will contribute its proprietary technologies to the therapeutic development of immune cell-based therapy candidates....
2022-06-07 12:23
3865
Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018
– Discovered in-house by the internal R&D Team at Antengene, ATG-018 is an orally-bioavailable, small molecule ataxia telangiectasia and Rad3-associated (ATR) kinase inhibitor that targets the DNA damage response (DDR) pathway. – This Phase I study will evaluate the safety, pharmacology and prelim...
2022-06-07 11:34
3799
ASCO 2022 | Ascentage Pharma Releases Updated Results Demonstrating the Therapeutic Potential of Alrizomadlin (APG-115) plus Pembrolizumab in Patients with Solid Tumors who Progressed on Immunotherapies
SUZHOU, China, and ROCKVILLE, Md., June 6, 2022 /PRNewswire/ -- scentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released the updated results from a Pha...
2022-06-07 11:30
2727
ASCO 2022 | The First Dataset of Olverembatinib (HQP1351) in Patients with GIST Demonstrates Therapeutic Potential with a Clinical Benefit Rate of 83.3%
SUZHOU, China, and ROCKVILLE, Md., June 6, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released the latest results from a Pha...
2022-06-07 11:28
2565
Pharmactive Enters Strategic Partnership with Nutraconnect for APAC
Pharmactive targets Asia Pacific Market with new collaboration
MADRID, June 7, 2022 /PRNewswire/ -- Pharmactive Biotech Products
2022-06-07 09:00
3088
iNtRON Completes GLP-TOX Studies of BAL200
* A novel drug candidate for anthrax received orphan drug designation (ODD) by the US FDA. BOSTON and SEOUL, Korea, June 6, 2022 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON" or "Company") announced today that the company has successfully completed the GLP toxicology studies of BAL200. The co...
2022-06-07 09:00
2724
CStone presents pre-specified overall survival data of sugemalimab for first-line treatment of stage IV non-small cell lung cancer at ASCO 2022
* Sugemalimab is the world's first PD-L1 monoclonal antibody to show the statistically significant and clinically meaningful overall survival improvement in combination with chemotherapy for patients with treatment-naïve stage IV non-small cell lung cancer across both squamous and non-squamous ...
2022-06-07 08:02
4643
Innovent and AnHeart Jointly Present Updated Phase 2 Efficacy and Safety Data of Taletrectinib (ROS1-TKI) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
* In 67 ROS1 TKI-naïve patients, the confirmed objective response rate (cORR) and disease control rate (DCR) were 92.5% and 95.5%, respectively. * In 38 crizotinib-pretreated patients, the cORR and DCR were 50% and 78.9%, respectively. * In 12 patients with brain metastasis and measurable...
2022-06-07 08:00
4197
Telix Showcasing Innovation in Theranostics at SNMMI
MELBOURNE, Australia and INDIANAPOLIS, June 7, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its presence at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting to be held inVancouver from June 11-14. Gallium-based pr...
2022-06-07 05:00
3166
MGI Announces Commercial Availability of DNBSEQ™ Sequencers* in the United States
SAN JOSE, Calif., June 6, 2022 /PRNewswire/ -- MGI Americas (MGI), today announced that its innovative CoolMPS sequencing chemistry and instruments* will become commercially available inthe United States beginning from August 29,2022. More details about the launch will be revealed at the 22nd ...
2022-06-07 00:59
2733
Week's Top Stories
Most Reposted
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 293 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 282 media titles]
2026-10-15 10:00SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 282 media titles]
2026-10-19 13:18
Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 280 media titles]
2026-10-15 12:59
DayOne Upsizes Malaysia Financing to US$7.2 Billion; Total Billings Surpass 1GW and Bookings Reach 2.3GW
[Picked up by 270 media titles]
2026-10-14 18:01Most Read
Sonilo Raises $11M to Build the AI-Native Audio Stack for Video
2026-10-15 00:00
26664
Agoda and Emerging Travel Group Enter Strategic Partnership
2026-10-15 16:00
16049